TFP‐2HCL, originally developed as an antipsychotic drug, has recently shown promise as a therapeutic agent in cancer treatment due to its potential to inhibit NUPR1, a protein implicated in tumor progression.[39, 40, 41] Studies have highlighted trifluoperazine as a promising candidate for cancer therapy, demonstrating its multifaceted anticancer properties. This evidence concerns the gene NUPR1 and neoplasm.